185 related articles for article (PubMed ID: 27869445)
1. [Breast cancer in BRCA1/2 mutation carriers].
Fabian P; Nenutil R
Cesk Patol; 2016; 52(4):206-209. PubMed ID: 27869445
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
3. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
4. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
8. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
[TBL] [Abstract][Full Text] [Related]
9. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
10. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
[TBL] [Abstract][Full Text] [Related]
11. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: effects of oral contraceptive use and parental origin of mutation.
Bernholtz S; Laitman Y; Kaufman B; Paluch Shimon S; Friedman E
Breast Cancer Res Treat; 2011 Sep; 129(2):557-63. PubMed ID: 21499684
[TBL] [Abstract][Full Text] [Related]
12. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
[TBL] [Abstract][Full Text] [Related]
13. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
[TBL] [Abstract][Full Text] [Related]
14. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
[TBL] [Abstract][Full Text] [Related]
16. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients.
Noh JM; Choi DH; Nam SJ; Lee JE; Kim JW; Kim SW; Kang E; Lee MH; Ahn SH; Kim KS; Park SK; Haffty BG;
Breast Cancer Res Treat; 2012 Jan; 131(1):217-22. PubMed ID: 21847643
[TBL] [Abstract][Full Text] [Related]
18. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
19. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
[TBL] [Abstract][Full Text] [Related]
20. Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?
Semple J; Metcalfe KA; Lubinski J; Huzarski T; Gronwald J; Armel S; Lynch HT; Karlan B; Foulkes W; Singer CF; Neuhausen SL; Eng C; Iqbal J; Narod SA;
Breast Cancer Res Treat; 2015 Nov; 154(1):163-9. PubMed ID: 26467043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
